Under the terms of the agreement, Beijing Med-Pharm will serve as the exclusive distributor of Anpo (ritodrine hydrochloride), a treatment for preterm labor, in mainland China. Beijing Med-Pharm will also provide sales and marketing support for the product.
Beijing Med-Pharm will distribute Anpo in both oral (10mg tablets) and injectable forms.
“We believe Beijing Med-Pharm will be able to rapidly increase the market share and brand awareness of Anpo,” said Dr Jeorge Ko, chairman of Taiwan Biotech. “Because the success of Anpo will establish the foundation for exploring additional collaborative opportunities in the future, this agreement has strategic importance for both companies.”
“Anpo is the recommended treatment for women with threatened preterm labor available in China and is an excellent fit with our growing portfolio of women’s health products,” added David Gao, CEO of Beijing Med-Pharm.